Last reviewed · How we verify
HBM9161 Dose A
At a glance
| Generic name | HBM9161 Dose A |
|---|---|
| Sponsor | Harbour BioMed (Guangzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis (PHASE3)
- Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients (PHASE3)
- A Study of HBM9161 in NMOSD Patients (PHASE1)
- A Phase I Study Evaluating the Safety, Tolerability, PK and PD in Healthy Chinese Volunteers (PHASE1)
- A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |